16 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
2
Synthesis, characterization, and optimization for in vivo delivery of a nonselective isopeptidase inhibitor as new antineoplastic agent.
University of Trieste
7
X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases.
Purdue University
4
Spongiacidin C, a pyrrole alkaloid from the marine sponge Stylissa massa, functions as a USP7 inhibitor.
Kumamoto University
42
Recent advances in the development of deubiquitinases inhibitors as antitumor agents.
China Pharmaceutical University
29
The discovery of potent USP2/USP8 dual-target inhibitors for the treatment of breast cancer via structure guided optimization of ML364.
China Pharmaceutical University
22
Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21.
Bayer
286
Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors.
Zhengzhou University
22
Discovery of Potent Small-Molecule USP8 Inhibitors for the Treatment of Breast Cancer through Regulating ERĪ± Expression.
China Pharmaceutical University
6
Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer.
Fudan University
36
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity.
Rapt Therapeutics
12
Advances in Discovering Deubiquitinating Enzyme (DUB) Inhibitors.
Dana-Farber Cancer Institute
28
Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies.
Progenra
1
Development of a highly reliable assay for ubiquitin-specific protease 2 inhibitors.
Shanghai Jiao Tong University
